Log In

 

Company Name : Takeda Pharmaceutical Company Limited

Friday, February 17, 2017 9:00AM IST (3:30AM GMT)

(BW)(MA-TAKEDA)

Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.


– Significantly Enhances Takeda’s Global Oncology Portfolio –; – Accretive to FY2018 Underlying Core Earnings –; – Reinforces Takeda’s Commitment to Developing Medicines for Patients Living with Cancer –


Osaka, Japan & Cambridge, Mass., United States

Takeda Pharmaceutical Company Limited (TSE:4502) (“Takeda”) announced the completion of its acquisition of ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) (“ARIAD”) for $24.00 per share in cash.

 

“We are very pleased to have completed the acquisition of ARIAD Pharmaceuticals. The addition of ARIAD’s innovative targeted therapies and research and development capabilities strengthens and diversifies our oncology business, positioning Takeda for sustainable long-term growth in this priority therapeutic area,” said Christophe Weber, president and chief executive officer of Takeda. “We are particularly excited by the global potential of brigatinib, an investigational drug product, which we believe will become a best-in-class ALK inhibitor for non-small cell lung cancer with the potential to achieve peak annual sales of over $1 billion. We are also impressed with the swiftness and agility of Takeda and ARIAD employees as they have planned for a successful integration while remaining focused on strategic goals. This bodes very well for the future of our combined business, and we look forward to building on this strong start to maximize the benefit of Iclusig® (ponatinib) and potential of brigatinib for cancer patients.”

 

“The acquisition of ARIAD is transformational for Takeda Oncology. Iclusig enhances our strong position in hematology in the U.S., and brigatinib has the potential to broaden our solid tumor franchise globally,” said Christophe Bianchi, president of Takeda Oncology. “There is a strong cultural fit between our two companies, with a shared mission to advance innovative therapies to improve the lives of patients with cancer. We have been working together over the past month to plan for a smooth integration of our businesses and we will work closely with regulatory authorities on our brigatinib market authorization submissions.”

 

Takeda continues to expect the transaction to be accretive to Underlying Core Earnings by FY2018. Strong revenue growth and synergy savings will offset increased sales and marketing costs for the anticipated brigatinib launch.

 

Tender Offer Details

 

Takeda completed the acquisition through a tender offer and subsequent merger of ARIAD with Kiku Merger Co., Inc., a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. ARIAD is now an indirect wholly owned subsidiary of Takeda.

 

The tender offer for all of the outstanding shares of ARIAD common stock expired as scheduled, immediately following the offer’s expiration time of 11:59 p.m., Eastern Time, on February 15, 2017. Computershare Trust Company, N.A., the depositary and paying agent for the tender offer, has advised Takeda that 158,558,628 shares of ARIAD common stock were tendered, representing approximately 81.4% of the shares outstanding. All of the conditions to the tender offer having been satisfied, Takeda’s indirect wholly owned subsidiary Kiku Merger Co., Inc. has accepted for payment and will promptly pay for all shares tendered. The transaction will be funded by approximately $3.5 billion of new debt and the remainder from existing cash. Takeda is expected to remain investment grade and the transaction has no impact on Takeda’s dividend policy.

 

On February 16, 2017, Takeda completed its acquisition of ARIAD through the merger of Kiku Merger Co., Inc. with ARIAD without a vote of ARIAD’s shareholders pursuant to Section 251(h) if the Delaware General Corporation Law. As a result of the merger, ARIAD became an indirect wholly owned subsidiary of Takeda. In connection with the merger, all ARIAD shares not purchased in the tender offer have been converted into the right to receive $24.00 per share in cash, without interest (less any required withholding taxes), the same amount paid for all shares validly tendered and not validly withdrawn in the tender offer. ARIAD common stock will cease to be traded on the NASDAQ Global Select Market.

 

Evercore Partners acted as financial advisor and Cleary Gottlieb Steen & Hamilton LLP acted as legal advisor to Takeda. J.P. Morgan Securities LLC, Goldman, Sachs & Co. and Lazard acted as financial advisors and Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as legal advisor to ARIAD.

 

About Takeda Pharmaceutical Company

 

Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. Additional information about Takeda is available through its corporate website, www.Takeda.com.

 

Please see Iclusig® (ponatinib) full Prescribing Information, including Boxed Warning.

 

Cautionary Statement Regarding Forward-Looking Statements

 

This press release contains forward-looking statements. When used in this press release, the words “can,” “will,” “believes,” “intends,” “expects,” “is expected,” similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements. Such statements are based on a number of assumptions that could ultimately prove inaccurate, and are subject to a number of risks. Neither Takeda nor ARIAD assumes any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.

 

 


Click here for Media Contact Details
CONTACTS : Media and Investors Takeda Investors Noriko Higuchi, +81 (0) 3-3278-2306 noriko.higuchi@Takeda.com or Takeda Media outside Japan Shawn Goodman, +1-415-250-0766 shawn.goodman@Takeda.com or Japanese Media Tsuyoshi Tada, +81 (0) 3-3278-2417 tsuyoshi.tada@Takeda.com or Finsbury Kal Goldberg, +1-646-805-2005 kal.goldberg@finsbury.com or Chris Ryall, +1-646-805-2078 chris.ryall@finsbury.com

More News from Takeda Pharmaceutical Company Limited

16/10/2017 5:22PM

Takeda Presents Updated Results from Pivotal Phase 2 ALTA Trial of ALUNBRIG™ (brigatinib) in ALK-Positive Non-Small Cell Lung Cancer

− Updated Results Continue to Support the Efficacy and Safety Findings for ALUNBRIG with the 180 mg Dosing Regimen in Patients with Advanced ALK+ NSCLC Who Have Progressed on Crizotinib, Per Independent Review ...

28/09/2017 8:00PM

Takeda to Feature ALUNBRIG™ (brigatinib) Data from Pivotal Phase 2 ALTA Trialat 18th World Conference on Lung Cancer

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the company will present four company-sponsored abstracts, including one oral presentation, at the 18th World Conference on Lung Cancer (WCLC) of ...

28/07/2017 12:10PM

Takeda Reports 1st Quarter FY2017 Results

Takeda Pharmaceutical Company Limited (TOKYO:4502):   Underlying Revenue growth of 6.6% led by Takeda's Growth Drivers   Underlying Revenue grew +6.6% with growth across all regions (U.S. +13.5%, Japan ...

Similar News

17/10/2017 11:40AM Image

New Delta Medical Power Supplies with PMBus Ver 1.3 Supported

Delta Electronics has launched two new AC/DC power supplies designed for use in both medical and industrial applications - the 600W Convection Cooled U-channel MEU-600C24 and the 1200W 1U Enclosed MEB-1K2A24. Both ...

No Image

17/10/2017 10:45AM

AstraZeneca and Chi-Med's Savolitinib Shows Encouraging Clinical Activity in 2nd-Line EGFR Mutation-positive Lung Cancer with MET-amplification

AstraZeneca and its partner Chi-Med today presented preliminary safety and clinical activity of savolitinib when given in combination with either Tagrisso (osimertinib) or Iressa (gefitinib) in two Phase Ib trials ...